These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 2494599)

  • 41. Prophylactic 1alpha-hydroxyvitamin D3 therapy in haemodialysis patients.
    Walker GS; Peacock M; Aaron J; Robinson PJ; Davison AM
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():125s-130s. PubMed ID: 606410
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Aluminium poisoning: dialysis encephalopathy, osteomalacia, and anaemia.
    Wills MR; Savory J
    Lancet; 1983 Jul; 2(8340):29-34. PubMed ID: 6134894
    [No Abstract]   [Full Text] [Related]  

  • 43. Aluminium-related osteomalacia: response to reverse osmosis water treatment.
    Smith GD; Winney RJ; McLean A; Robson JS
    Kidney Int; 1987 Jul; 32(1):96-101. PubMed ID: 3626303
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evidence for aluminium accumulation in renal failure.
    Marsden SN; Parkinson IS; Ward MK; Ellis HA; Kerr DN
    Proc Eur Dial Transplant Assoc; 1979; 16():588-96. PubMed ID: 549003
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis.
    Slatopolsky E; Weerts C; Lopez-Hilker S; Norwood K; Zink M; Windus D; Delmez J
    N Engl J Med; 1986 Jul; 315(3):157-61. PubMed ID: 3724805
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Risk of orally administered aluminium hydroxide and results of withdrawal.
    Bournerias F; Monnier N; Reveillaud RJ
    Proc Eur Dial Transplant Assoc; 1983; 20():207-12. PubMed ID: 6657657
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Magnesium hydroxide as a complementary aluminium-free phosphate binder to moderate doses of oral calcium in uraemic patients on chronic haemodialysis: lack of deleterious effect on bone mineralisation.
    Morinière P; Vinatier I; Westeel PF; Cohemsolal M; Belbrik S; Abdulmassih Z; Hocine C; Marie A; Leflon P; Roche D
    Nephrol Dial Transplant; 1988; 3(5):651-6. PubMed ID: 3146723
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Indirect evaluation of the effect of 1 alpha-hydroxyvitamin D3 on intestinal absorption of aluminum].
    Demontis R; Reissi D; Noël C; Morinière P; Renaud H; Leflon P; Westeel PF; Brasseur J; Coevoet B; Fournier A
    Nephrologie; 1988; 9(3):135-8. PubMed ID: 3194044
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Desferrioxamine treatment of osteomalacia caused by aluminum poisoning].
    Charhon SA; Chavassieux P; Chapuy MC; Accominotti M; Traeger J; Meunier PJ
    Presse Med; 1986 Jan; 15(2):55-9. PubMed ID: 2935857
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Treatment of aluminum-induced osteopathy with desferrioxamine in dialysis-dependent renal failure].
    Lechleitner P; Gmeiner R; Beck G; König P
    Wien Med Wochenschr; 1987 Aug; 137(14-15):355-60. PubMed ID: 3673100
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Suppression of secondary hyperparathyroidism in children with chronic renal failure by high dose phosphate binders: calcium carbonate versus aluminium hydroxide.
    Mak RH; Turner C; Thompson T; Powell H; Haycock GB; Chantler C
    Br Med J (Clin Res Ed); 1985 Sep; 291(6496):623-7. PubMed ID: 3928054
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Renal osteopathy and bone mineralisation in patients treated with dihydrotachysterol during long term dialysis (author's transl)].
    Pogglitsch H; Schmidberger H; Gell G
    MMW Munch Med Wochenschr; 1976 Jan; 118(5):131-6. PubMed ID: 814443
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Silicon and aluminium interactions in haemodialysis patients.
    Parry R; Plowman D; Delves HT; Roberts NB; Birchall JD; Bellia JP; Davenport A; Ahmad R; Fahal I; Altmann P
    Nephrol Dial Transplant; 1998 Jul; 13(7):1759-62. PubMed ID: 9681724
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Disappearance of vascular calcifications during treatment of renal osteodystrophy. Two patients treated with high doses of vitamin D and aluminum hydroxide.
    Verberckmoes R; Bouillon R; Krempien B
    Ann Intern Med; 1975 Apr; 82(4):529-33. PubMed ID: 1119767
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Aluminum and renal osteodystrophy.
    Nebeker HG; Coburn JW
    Annu Rev Med; 1986; 37():79-95. PubMed ID: 3085581
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Renal osteodystrophy: aluminium and secondary hyperparathyroidism].
    de Vernejoul MC
    Rev Prat; 1990 Mar; 40(7):613-8. PubMed ID: 2326587
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The use of calcium carbonate to treat the hyperphosphataemia of chronic renal failure.
    Williams B; Vennegoor M; O'Nunan T; Walls J
    Nephrol Dial Transplant; 1989; 4(8):725-9. PubMed ID: 2510082
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bone histoquantitative findings and histochemical staining reactions for aluminium in chronic renal failure patients treated with haemodialysis fluids containing high and low concentrations of aluminium.
    McClure J; Fazzalari NL; Fassett RG; Pugsley DJ
    J Clin Pathol; 1983 Nov; 36(11):1281-7. PubMed ID: 6630577
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The influence of a high calcium carbonate intake on bone disease in patients undergoing hemodialysis.
    Meyrier A; Marsac J; Richet G
    Kidney Int; 1973 Aug; 4(2):146-53. PubMed ID: 4744972
    [No Abstract]   [Full Text] [Related]  

  • 60. Risk factors in aluminum toxicity in children with chronic renal failure.
    Santos F; Massie MD; Chan JC
    Nephron; 1986; 42(3):189-95. PubMed ID: 3511396
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.